Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston
4
×
boston blog main
boston top stories
fda
life sciences
national blog main
patisiran
4
×
clinical trials
hereditary transthyretin amyloidosis
national top stories
onpattro
rna interference
akcea therapeutics
drugs
inotersen
new york blog main
new york top stories
pfizer
san diego blog main
san diego top stories
tafamidis
acute hepatic porphyrias
akin akinc
alexion pharmaceuticals
aminolevulinic acid
andrew fire
biotech
boehringer ingelheim
craig mello
deals
dicerna pharamceuticals
european medicines agency
givosiran
harvard pilgrim health care
hepatitis b
hepatitis b virus
institute for clinical and economic review
john maraganore
nobel prize
What
drug
4
×
alnylam
fda
medicine
pharmaceuticals
rnai
gene
interference
protein
rna
afternoon
ago
alnylam’s
approval
approved
approves
caught
causing
cells
dicerna
disease
ema
employ
europe
eye
follows
gets
harmful
hepatitis
history
hits
indicated
intended
landmark
make
making
medicines
method
mute
nod
Language
unset
Current search:
boston
×
patisiran
×
drug
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug